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Abstract
Although understanding the local epidemiology of gonorrhea is critical for local efforts, 
understanding the multinational epidemiology may support development of national and 
international prevention and control policies and strategies. In this paper, we review current 
epidemiology of gonorrhea through an international lens and with a focus on selected populations. 
The World Health Organization (WHO) estimates that ~87 million new gonococcal infections 
occurred among 15–49 year olds in 2016. Gonorrhea rates are rising in many countries. Gay, 
bisexual, and other men who have sex with men, racial/ethnic minorities, indigenous populations, 
and sex workers appear to bear disproportionate burdens of gonorrhea. International travel can 
facilitate spread of gonorrhea, including resistant strains, across international borders. We 
highlight critical gaps in epidemiological knowledge, including data on gonorrhea among 
transgender persons and the burden of extragenital gonorrhea. Even as we continue to gather data, 
action — informed by currently available data — is needed now to confront this growing 
international threat.
Summary text for the online Table of Contents:
Better understanding of the international epidemiology of gonorrhoea may inform national and 
international prevention and control strategies and among whom to focus resources. We review the 
current epidemiology of gonorrhoea through an international lens. Sexual, gender, racial and 
ethnic minorities are disproportionately affected by gonorrhoea, but gaps in knowledge, such as 
the epidemiology of gonorrhoea among transgender people, should be addressed.
BACKGROUND
Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria 
gonorrhoeae. Following transmission, N. gonorrhoeae infects mucosa of exposed anatomic 
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sites, such as the urogenital tract, rectum, pharynx, and conjunctivae. N. gonorrhoeae is 
fairly easily transmitted: the estimated probability of penile-to-vaginal transmission is 
approximately 50% per sex act, and of vaginal-to-penile transmission is approximately 20% 
per act.1–3 Probabilities of per-condomless act transmission during oral (63% urethral-to-
pharyngeal and 9% pharyngeal-to-urethral) and anal sex (84% urethral-to-rectal and 2% 
rectal-to-urethral) have been estimated from mathematical models.4
Urethral infections in cisgender men and other people with penises provide a useful marker 
of incident infection because symptoms generally develop within a week of exposure and — 
in areas where healthcare is available — the symptoms of gonococcal urethritis (e.g., 
profuse purulent discharge and painful urination) prompt people to seek care, diagnosis, and 
treatment in a timely manner. In contrast, rectal, pharyngeal, and cervical infections are 
often asymptomatic and most often detected through screening. As a result, case rates of 
infections at these anatomic sites are likely to be heavily influence by screening practices. In 
populations in which oral or anal sex is common, asymptomatic infections at these anatomic 
sites might be more likely to be prevalent at a given point in time than urethral infections 
(which may be promptly treated if symptomatic). In the absence of screening for 
asymptomatic infections, undetected gonococcal infections may be considerable.
If not treated in a timely manner, cervical gonorrhea can lead to severe reproductive health 
complications, such as pelvic inflammatory disease (PID), chronic pelvic pain, ectopic 
pregnancies, and tubal factor infertility. Gonococcal infections during pregnancy have been 
associated with chorioamnionitis, premature rupture of members (PROM), preterm birth, 
low birth weight, and spontaneous abortions.5–8 Infants born to mothers with untreated 
cervical gonorrhea can develop hyperacute conjunctivitis (neonatal ophthalmia), which can 
rapidly lead to corneal perforation and blindness if not rapidly treated. Infrequently, 
gonorrhea can progress to bacteremia and systemic involvement (disseminated gonococcal 
infection), leading to septic arthritis, endocarditis, and rarely, meningitis. Gonorrhea is also 
associated with heightened risk of HIV acquisition and transmission.9–11
Particularly in countries where diagnostic testing and screening for gonorrhea are readily 
available, prompt detection and effective treatment prevent sequelae and further 
transmission. However, provision of effective treatment is under threat, as N. gonorrhoeae 
has successively acquired antimicrobial resistance to each antimicrobial agent used and 
recommended for treatment.12 The confluence of emerging resistance to cephalosporins and 
macrolides and a dwindling antimicrobial development pipeline threatens to undermine 
gonorrhea control and worsen ongoing management challenges.
To address the threat of gonorrhea globally, prevention and control programs need to be 
strengthened and novel prevention approaches are needed. A robust and current 
understanding of the epidemiology of gonorrhea can inform these efforts. Although 
understanding the local epidemiology of gonorrhea is critical for local efforts, understanding 
the multinational epidemiology may inform national and international prevention and 
control policies and approaches. In this paper, we review the current epidemiology of 
gonorrhea through an international lens and with a focus on selected populations.
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We searched for articles published between 2009 and 2019 in PubMed® without language 
restrictions, using PubMed Medical subject heading (MeSH) terms in the following 
literature search strategy: (“Neisseria gonorrhoeae” OR gonorrhoea OR gonococcal OR 
gonococci OR gonococcus OR STI or “sexually transmitted infection” OR STD OR 
“sexually transmitted diseases”) AND (Epidemiolog* OR epidemic* OR outbreak OR 
sexual network* OR risk* OR behavior* OR trend* OR prevalence OR incidence OR 
phylogeny*) AND (“Men who have sex with men” OR MSM OR gay OR bisexual OR 
transgender* OR black OR African* OR Caribbean* OR indigenous OR aborigin* OR “first 
nation” OR “native American” OR “American Indian” OR race OR ethnic* OR “sex work” 
OR “sex workers” OR “sex worker” OR travel* Or “sex abroad” OR disparities OR “health 
inequity” OR “health inequity” OR “health inequality” OR “Health Status Disparities”). We 
reviewed the generated list of 6,496 articles for relevance and hand-searched bibliographies.
INTERNATIONAL OVERVIEW
The World Health Organization (WHO) estimated the pooled 2016 global prevalence of 
urogenital gonorrhea (the proportion of the world’s population with gonorrhea in a given 
year) to be 0.9% in women and 0.7% in men, corresponding to a total of 30.6 million 
gonorrhea cases worldwide.13 By region, prevalence among women was highest in the WHO 
African region (1.9%), the region of the Americas (0.9%) and the Western Pacific region 
(0.9%), and were lowest in the European region (0.3%). Similarly among men, prevalence 
was highest in the African region (1.6%), the Americas (0.8%) and Western Pacific (0.7) and 
lowest in Europe (0.3%). Likely owing to differences in healthcare infrastructure and 
availability of screening and treatment, countries categorized as low-income by World Bank 
criteria had the higher prevalences than those categorized as high-income.13 Prevalence 
estimates from specific countries further highlight heterogeneity across geographic areas. 
From 1999–2008, the overall prevalence of urogenital gonorrhea in the United States (USA) 
was 0.3%; during 2010–2012, the gonorrhea prevalence was <0.1% in Great Britain.14,15 
Among young adults in Peru, the prevalence was similarly low (0.1%) in 2002.16 In contrast, 
the pooled prevalence across studies of 15–24 years old in South Africa was 4.6%, and 
across studies of higher risk 15–24 year olds in East Africa was 8.2%.17
Incidence rate, a measure of new infections or diagnoses in a specific time period, was 20 
per 1000 women and 26 per 1000 men globally in 2016, translating into 86.9 million new 
cases. Incidence was highest in the WHO African Region, the Americas, and Western 
Pacific, and lowest in the European region.13
National case report data complement WHO estimates and allow interpretation of trends. 
Reliable case report data are generally available only from high-income countries, as 
systematic, representative, and timely collection and submission of case reports to national 
public health agencies require well-functioning clinical, laboratory, and public health 
infrastructures. Importantly, gonorrhea case rates are influenced not only by incidence of 
infection, but also by factors such as screening and testing practices and completeness of 
case reporting. In many countries, gonorrhea case rates have increased recently. In the USA, 
case rates increased 75.2% from 2009 (98.1 per 100,000) to 2017 (171.9 per 100,000).18 
Similarly, case rates increased in Australia (65.5 per 100,000 in 2013 to 118.0 per 100,000 
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in 2017) and Canada (33.5 per 100,000 in 2010 to 55.4 per 100,000 in 2015) 19,20 Although 
case rates did not increase in all countries in the European Union (EU)/European Economic 
Area (EEA), the overall gonorrhea notification rate in the European Union(EU)/European 
Economic Area (EEA) increased during 2012–2016 with a few fluctuations.21 The largest 
relative increases in rates within the EU/EEA during 2015–2016 were observed in Iceland 
(108.7% increase: 13.7 to 28.6), Ireland (49.1% increase: 27.7 to 41.3), Finland (49.0% 
increase: 5.1 to 7.6), and Spain (36.1% increase: 10.8 to 14.7).21 The rate of gonorrhea 
diagnoses in England rose steadily from 2008 (28.9 per 100,000) to 2018 (101.1 per 
100,000), with a momentary decline in 2016.22 In the USA, England, Australia, Canada, and 
nearly all EU/EEA countries, rates were often highest among adolescents and young adults 
and were higher (and increasing more rapidly) among men than women.18–22
SELECTED POPULATIONS
Some populations have historically been disproportionately affected by gonorrhea, 
marginalized and at greater risk for poor sexual health outcomes, and/or might play 
important roles in transmission. In this section, we summarize epidemiological data 
published during the past decade on gonorrhea in several of these populations, the 
epidemiological importance of these populations, and the factors likely contributing to 
disease acquisition or transmission within each population.
Gay, bisexual, and other men who have sex with men
In many countries, data about gonorrhea among gay, bisexual, and other men who have sex 
with men (hereafter referred to as MSM) are limited by poor surveillance and lack of 
elicitation of gender of sex partners by healthcare providers or researchers (often owing to 
stigma and discrimination).21,23 Recent national case-report data from high-income 
countries suggest that a disproportionately high percentage of gonococcal infections occur 
among MSM.18,21,24 In 15 EU/EEA countries that reported mode of transmission for at least 
60% of all cases to the European Centre for Disease Prevention and Control (ECDC) in 
2016, 46% of cases were among MSM.21 In England (where data on gender and gender of 
sex partners were available for nearly all cases), 51.6% of cases in 2014 were among MSM.
24
 Because of widespread use of electronic laboratory reporting in the USA, gender of sex 
partner is not routinely collected in case reports in this country. Yet the gonorrhea male-to-
female rate ratio increased from slightly less than 1.0 in 2012 to 1.4 in 2017, hinting that sex 
between men contributed to increasing rates.18 More compelling are supplemental data from 
the US-based sentinel surveillance system, the STD Surveillance Network: overall, 26.5% of 
gonococcal infections in participating jurisdictions were in MSM in 2017, with a range by 
jurisdiction of 20% in Florida to over 80% in San Francisco, California.18
Gonorrhea prevalence or test positivity estimates from cross-sectional studies of MSM are 
more widely available, including from middle- and low-income countries. Prevalence or test 
positivity estimates were elevated across studies of MSM, but estimates varied substantially 
by the sampled population. As expected, test positivity was highest among MSM attending 
STI clinics: 35% among 229 STI clinic attendees in Guatemala and 22% among 463 men in 
Guangzhou, China (including 7.2% rectal positivity and 3.9% pharyngeal positivity).25,26 In 
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over 10,000 MSM tested in 42 STD clinics in the United States during 2010–2012, 11.1% 
tested positive for urethral gonorrhea, 10.2% tested positive for rectal gonorrhea, and 7.9% 
tested positive for pharyngeal gonorrhea.27 Much lower test positivity was found among 
MSM who were enrolled in cohort studies or sampled through respondent-driven sampling 
in Brazil, Thailand, coastal Kenya, and Uganda: 1.4–1.8% had urethral gonorrhea, 1.8–9% 
had rectal gonorrhea, and 0.5% pharyngeal gonorrhea at baseline.28–31 In one of the most 
robust estimates of community prevalence to date, a recently-conducted multisite assessment 
of 2,077 MSM attending community venues, such as bars and clubs, in the USA 
demonstrated a 4.5% prevalence of rectal gonorrhea and 4.6% prevalence of pharyngeal 
gonorrhea.32
Not only is gonorrhea prevalent among MSM, but the incidence of gonococcal infections 
may be increasing among MSM, at least in high-income countries. In a retrospective cohort 
of MSM attending sexual health clinics in Australia, gonorrhea incidence among MSM was 
calculated as having increased from 14.1 per 100 person-years (PY) in 2010 to 24.6/100 PY 
in 2017, with the greatest increases in incidence at oropharyngeal and rectal sites.33 Similar 
trends have been observed in England, Ireland, Spain, the USA, and Canada.22,34–38
While some observed increases in gonorrhea diagnoses among MSM may be due in part to 
expanded extragenital screening, routine screening as a component of HIV pre-exposure 
prophylaxis (PrEP), and high throughput screening clinics for MSM in many countries, 
changes in testing alone are unlikely to account for the entirety of the observed increases.
18,24,37
 Gonorrhea incidence among MSM appears to be increasing. These gonorrhea 
increases parallel those of other STIs among MSM, including infectious syphilis, 
lymphogranuloma venereum, and even sexually transmitted enteric infections.18,39,40 
Gonorrhea among MSM is likely associated with increased numbers of sexual partnerships, 
concurrency, heightened density of same-sex sexual networks, and high underlying 
prevalence of gonorrhea within sexual networks.41,42 In addition, condom use among MSM, 
including during anal sex, has declined.43–45 Increasing use of geospatial applications to find 
sex partners, use of HIV seroadaptive behaviors, the introduction of HIV PrEP, and 
proliferation of circuit parties and group sex events, particularly those involving chemsex, 
might contribute to changes in behavior and development of large and dense sexual networks 
that may facilitate gonorrhea transmission.46–57
Emerging gonococcal antimicrobial resistance — particularly resistance to the only 
remaining currently recommended antimicrobials — among MSM is of grave concern. 
While the pattern is not universal, gonococcal isolates from MSM often demonstrate greater 
prevalence of antimicrobial resistance than isolates from heterosexuals.58–61 Although new 
resistant strains are often initially detected in heterosexuals, such strains can disseminate 
rapidly in sexual networks of MSM.62–64 The spread of resistant strains among MSM may 
be facilitated by the partnership and network phenomena outlined above. Furthermore, 
infection of the oropharynx (which is often asymptomatic, undiagnosed, and prevalent 
among MSM) might also contribute to emergence of antimicrobial resistance among MSM. 
Pharyngeal gonorrhea can be difficult to treat with recommended therapy (perhaps 
enhancing selection for resistant strains) and may have enabled, through horizontal gene 
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transfer from commensal microorganisms, acquisition of mosaic penA genes responsible for 
most resistance to extended-spectrum cephalosporins.65
Transgender persons
Transgender is an umbrella term used to describe a group of individuals whose gender 
identity and/or presentation differs from the sex which they were assigned at birth.66 This 
umbrella classification, though important for advancing epidemiological research and 
clinical care, belies substantial heterogeneity of identity, behavior, use of body modifications 
or gender-affirming therapy, sexual orientation, and STI risk.66,67 In this section, we also 
include third-gender, non-binary, and other gender-variant populations, such as the hijra 
community in South Asia.
Although data on gonorrhea among transgender people are limited, transgender people bear 
a strikingly disproportionate burden of HIV.66,68,69 Available data have highlighted several 
factors thought to contribute to heightened STI risk: societal transphobia, discrimination, 
and experiences of abuse; lack of legal authorization for gender-congruent identification; 
barriers to gender-affirming healthcare; poverty; mood disorders; internalized transphobia 
contributing to depression and substance abuse; and particularly germane to STI risk, 
difficulty finding employment with resulting engagement with sex work and transactional 
sex, and condomless receptive anal intercourse.67,69–71 A disproportionate incidence or 
prevalence of gonorrhea is probable and worthy of exploration.
Available data do suggest a substantial prevalence of gonorrhea among transgender women, 
particularly at extragenital anatomic sites. Whereas the gonorrhea positivity of urogenital 
specimens ranged from 0.1% (among 764 women from drop-in centers in Thailand) to 2.8% 
(among 406 STI clinic attendees at multiple sites in the USA), positivity of pharyngeal 
specimens ranged from 3.5%–37.3% across studies (with positivity of 8.1%–9.8% in the two 
largest studies from Thailand and the USA).72–75 Positivity among rectal specimens ranged 
from 6.3%–43% (9.6%–11.8% in the Thailand and USA studies).72–76 Two studies that did 
not mention anatomic site of specimen collection found a prevalence among transgender 
women of 2.1% (among 63 young adults in the USA) and 4% (among 77 STI clinic 
attendees in Australia).77,78
Although data on transgender men are even more scarce, available data hint at high 
gonorrhea prevalence. Among 105 transgender men attending STI clinics, urogenital 
positivity was 7.1%, pharyngeal positivity was 5.9%, and rectal positivity was 14.7%.74 
Comparably, positivity was found among other samples in San Francisco, California, USA 
and Melbourne, Australia.73,78 In contrast, none of the 82 transgender male youth attending 
a community health clinic in Boston, Massachusetts, USA had gonorrhea.77
A single study of gonorrhea among persons identified as hijras, a long-recognized third 
gender in South Asia, found a 4% prevalence of urethral gonorrhea and 0% prevalence of 
rectal gonorrhea among 203 persons from Lahore, Pakistan, and 4% and 29% prevalence, 
respectively, among 206 persons from Karachi, Pakistan.79
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Racial/ethnic minorities and indigenous populations
Because racial/ethnic categories are not routinely collected as part of STI surveillance in 
most high-income countries and few cross-sectional data stratified by race/ethnicity are 
available, data on gonorrhea among racial/ethnic minorities across the globe are limited. 
Available data include recent case report data from the USA and England and test positivity 
data from Honduras. In the USA and England (two countries in which race/ethnicity is 
routinely collected as part of gonorrhea case reports), people of black race/ethnicity have the 
highest population rates of reported gonorrhea.18,22 In the USA, the overall rate of reported 
gonorrhea cases among Blacks in 2017 was 8.3 times the rate among Whites (548.1 per 
100,000 among Blacks and 66.4 per 100,000 among Whites). Among Blacks, particularly 
high rates were observed in women aged 20–24 years (2066.8 per 100,000) and men in the 
same age category (2154.8 per 100,000).18 In England, the highest population diagnosis rate 
by ethnicity was also among people of black ethnicity (nearly 300 per 100,000 in 2017).22 
Within this group, black Caribbean and black non-Caribbean/non-African people had the 
highest diagnosis rate of all ethnic groups (4–6 times the rates of White British), whereas 
black Africans had relatively low rates (over twice the rate of White British, but comparable 
to rates among White Irish).80 Among the Garifuna, an ethnic minority of African-
Caribbean origin, in Honduras, the prevalence of urogenital gonorrhea was high among 
women (1.8%) but relatively low (0.3%) in men.81 In the USA, Hispanic/Latinx people also 
bear disproportionate rates of gonorrhea. In 2017, the rate of reported gonorrhea cases 
among Hispanic/Latinx people, at 113.7 per 100,000, was 1.7 times the rate among Whites.
18
In the USA, Canada, and Australia, indigenous populations bear disproportionate rates of 
STIs, including gonorrhea. In the USA, the rate of reported gonorrhea cases among 
American Indians/Alaska Natives (AIAN) (301.9 cases per 100,000) was nearly 5 times the 
rate among Whites in 2017.18 AIAN women 20–24 years had rates as high as 1,037.7 per 
100,000 in 2017. Gonorrhea rates in Canada have been highest in the two provinces where 
Indigenous peoples comprise the majority of the population: the 2015 rate in the Canadian 
Northwest Territories (815.9 per 100,000) and Nunavut (837.6) were approximately 15 times 
the national average.20 In Australia, rates of gonorrhea in 2016 among Aboriginal and Torres 
Strait Islander people (581.8 per 100,000) were 7 times the rate of non-Indigenous people.82 
Among Aboriginal and Torres Strait Islander people, women aged 15–19 years had the 
highest rate of 2,710.0 per 100,000.
The marked inequities by race/ethnicity and among indigenous peoples are not explained by 
differences in individual behavior. Legacies and enduring effects of mistreatment, 
institutional racism (including residential segregation and persistent inequalities in income, 
wealth, education, housing and living conditions, access to healthcare, and incarceration 
rates) contribute to poor health outcomes and support observed inequities.80,83–89 
Assortative mixing within networks of persons with high gonorrhea prevalence further 
reinforces disease transmission.84,89 In the USA, undocumented Latinx immigrants also face 
substantial barriers to healthcare access.85,90,91 Among indigenous populations, legacies of 
mistreatment and forced dislocation from traditional lands, communities, and culture likely 
played critical roles in giving rise to current structural determinants, including poverty, 
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educational disadvantage, poor living conditions, and barriers to accessing high-quality 
healthcare.91–97 These factors in turn contribute to substance abuse and poor sexual health 
outcomes (young age of sexual debut, inconsistent condom use, and multiple partners) 
among indigenous youth.97
Sex workers
The category of sex workers (SWs) encompasses a diverse population who exchange sexual 
activity for income, employment, survival (e.g., food or shelter), and/or drugs. They include 
persons of all genders, span the socioeconomic range from the economically disadvantaged 
engaging in survival sex to escorts of higher socioeconomic status (SES), and likely vary in 
STI risk. The Joint United National Programme on HIV/AIDS (UNAIDS) has estimated that 
approximately 8 million persons are classified as SWs globally.98
Recently published estimates of urogenital gonorrhea positivity among female SWs range 
from 2.7% among women attending STI clinics in England in 2011 (n=2,534) to 21.2% 
among those attending STI clinics in Guatemala in 2012 (n=3,213).99–104 Data on 
prevalence of rectal and pharyngeal gonorrhea among female SWs are sparse, but a large 
retrospective cohort study of 18,475 FSWs attending 42 sexual health clinics in Australia 
during 2009–2015 reported an overall incidence of urogenital gonorrhea of 1.4/100 PY, of 
pharyngeal gonorrhea was 3.6/100 PY, and of rectal gonorrhea was 0.3/100 PY.105 The 
annual incidence of each increased during the analytic period, including from 1.6/100 PY in 
2009 to 4.9/100 PY in 2015 for pharyngeal gonorrhea.
Recent case reports hint that female SWs might be at elevated risk of acquisition and 
transmission of antimicrobial-resistant N. gonorrhoeae. In 2009, Ohnishi et al reported the 
first case of ceftriaxone-resistant N. gonorrhoeae (MIC=2 μg/ml), identified in a 31-year-old 
female SW with pharyngeal gonorrhea who had visited a clinic in Kyoto, Japan.106 More 
recently, Katz et al reported a cluster in Hawaii, USA, of N. gonorrhoeae isolates with high-
level azithromycin resistance (MICs ≥256 μg/ml) and decreased ceftriaxone susceptibility 
(MICs 0.06–0.125 μg/ml).108 Four of the six male cases reported recent contact with female 
SWs in Honolulu.
Although data are sparse for male SWs, recently published data have provided estimates of 
prevalence by anatomic site. Among 53 male SWs in Tel Aviv, Israel, 1.8% had urethral 
gonorrhea and 7.5% had pharyngeal gonorrhea.108 Rectal gonorrhea positivity was 9.9% 
among 334 male SWs in India and 8.5% among 96 men attending a sex worker clinic in 
Abidjan, Côte d’Ivoire.109,110 In estimates that aggregated infections by anatomic site, 
17.4% of 488 male clinic-attending SWs in England had gonorrhea (a markedly higher 
positivity than the 2.8% positivity among other male clinic attendees). 111
SWs experience multiple and layered risks that heighten their risk of STIs including 
gonorrhea. At the most proximate, inconsistent condom use with clients and other partners 
increases gonorrhea acquisition risk. Yet misogyny, sexual violence and physical abuse, 
substance abuse, financial coercion, and inaccessibility of condoms may limit the ability of 
SWs to negotiate condom use.101,112–116 The percentage of SWs reporting condomless sex 
with clients or difficulty using condoms with clients ranged from 2.1% among female SWs 
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in South Africa to 70% among male SWs in India.101,112,113,115–118 Drug use has been 
commonly described, and has been associated with greater numbers of clients, forced sex, 
and unstable housing.119,120 Some cities have clinics dedicated to SW care; however, SWs 
who lack access to such clinics may face barriers to sexual health services due to lack of 
health insurance, mistrust of the healthcare system, local reliance on syndromic 
management, and concern that positive tests may adversely affect their ability to work. 
Transgender and male SWs may also face intersectional compounded vulnerabilities based 
on transphobia and homophobia.121
International travelers
Air travel and increased globalization fuel rapid human mobility across international 
borders, which in turn can facilitate international spread of infectious diseases. During 
1980–2016, the number of international travelers increased from 278 million to 1.2 billion.
122
 Sexual mixing with partners from other countries while traveling can facilitate 
international spread of STIs, including gonorrhea. A large meta-analysis of sexual risk-
taking during international travel reported a pooled prevalence of sex with a new partner 
abroad of 34% (range by studied population: 4% to 86% of young British seasonal workers 
in Ibiza).123 Across studies, 16.8% (pooled estimate) reported having engaged in 
condomless sex while traveling.
Available data from Nordic countries (Denmark, Finland, Norway, and Sweden) indicate a 
substantial proportion of diagnosed gonorrhea cases were travel-associated. During 2008–
2013, 25.5% of 12,645 gonorrhea cases were deemed travel-associated, of which 86% 
(n=2,432) were in men; 652 (26.8%) were identified as MSM.124 Nearly half of travel-
associated cases were thought to have been acquired in Asia — particularly Thailand (31.2% 
of travel-associated cases) and the Philippines (8.0%) — and 32% acquired in Europe. The 
highest proportions were from Spain (7.1%) and Germany (6.2%).
Multiple case reports over several decades have underscored the contribution of international 
travel, especially travel from Southeast Asia or the Western Pacific Region, to the spread of 
antimicrobial-resistant N. gonorrhoeae. In 1976, the first reported cases of penicillinase-
producing Neisseria gonorrhoeae (PPNG) were identified in an American service member 
recently returned from Southeast Asia, and a woman in the United Kingdom with PID.
125,126
 The PPNG strains probably had their origins in independent genetic events in 
southeast Asia and West Africa.127 Over subsequent decades, fluoroquinolone-resistant 
strains and then cephalosporin-resistant strains appeared to emerge first in east Asia before 
spreading globally via international travel (and at times through international linkages of sex 
work).128–138
Recently identified cases of ceftriaxone-resistant strains, seemingly spread via international 
travel, highlight the importance of condom use and other safer sex approaches during travel. 
Two recent cases of ceftriaxone-resistant gonorrhea were identified in the UK, both of which 
occurred in heterosexual men recently returned from east or southeast Asia.139,140 Two cases 
were identified in Australia, one of whom had recently had sex in southeast Asia.141 In late 
2018, two additional cases (with high ceftriaxone and azithromycin MICs) were associated 
with travel of UK nationals to a popular holiday destination in Spain.142 Although recent 
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ceftriaxone-resistant infections were identified in the UK and Australia, it seems probable 
that they were identified because of robust surveillance in these countries. The strains may 
be circulating elsewhere, though as of yet undetected.
Conclusions
As this review highlights, gonorrhea disproportionately affects marginalized populations. 
The prevalence of gonorrhea among sexually-active young adults living in low-income 
countries, and — in many countries —among sexual and gender minorities, racial/ethnic 
minorities and indigenous communities, and sex workers is markedly higher than among the 
general population in high-income countries. Increasing gonorrhea incidence and emerging 
antimicrobial resistance, which will undermine prevention and control efforts, will likely 
worsen and compound these health inequities.
Particularly in light of limited public health resources available to address this expanding 
public health threat, available prevention and control approaches — for gonorrhea and 
antimicrobial-resistant strains — can be tailored to the populations most at risk. In high-
income countries, sexually-active persons within sexual, gender, and racial/ethnic minority 
groups can be prioritized. Ensuring access to high-quality and culturally competent sexual 
healthcare, with ascertainment of sexual histories and adherence to screening 
recommendations, is crucial. Expanded testing and screening, such as through routine STI 
testing as part of PrEP, self-collection of specimens, or use of point-of-care tests, might 
support prevention and control efforts. Tackling deeper structural determinants of health, 
which might be more impactful on a population-level, will prove far more challenging and 
will require sustained multisectoral coordination and investment. In low-income countries, 
where diagnostic testing is rarely available and care is frequently rendered as syndromic 
management, prevention and control is far more challenging. Renewed support for condom 
promotion for primary prevention is worth considering. In many countries, regardless of the 
resources available for the public health and clinical infrastructure, gonorrhea is increasing: 
clearly new prevention approaches, such as an affordable and effective vaccine, are urgently 
needed.
Continuing to advance our understanding of the epidemiology of gonorrhea is critical. 
Strengthening surveillance across the globe, such as through greater adoption of 
standardized case definitions with reporting of a minimum dataset on cases, sentinel 
surveillance, or — in resource-limited settings — syndromic surveillance with periodic 
laboratory testing, can advance this effort. Strengthening surveillance of N. gonorrhoeae 
antimicrobial resistance can also play an important role. Existing gaps in our knowledge 
about the risks of gonorrhea among transgender people, including the risks of infection at 
different anatomic sites, need to be urgently addressed. Better data on the incidence of 
gonorrhea, especially at different anatomic sites, can be used to optimize screening 
recommendations. Addressing existing gaps in knowledge about dynamic sexual networks 
and N. gonorrhoeae transmission within communities and networks further refine decision-
making about the value of partner services and contact tracing. Although continued 
epidemiological investigations are important, N. gonorrhoeae is unlikely to wait for us to fill 
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in all the gaps. So even as we continue to gather data, action — informed by currently 
available data — is needed now to confront this growing international threat.
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